Woodline Partners LP Buys 19,538 Shares of Disc Medicine, Inc. (NASDAQ:IRON)

Woodline Partners LP grew its position in Disc Medicine, Inc. (NASDAQ:IRON - Free Report) by 5.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 396,600 shares of the company's stock after purchasing an additional 19,538 shares during the quarter. Woodline Partners LP owned about 1.33% of Disc Medicine worth $25,144,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Renaissance Technologies LLC acquired a new stake in Disc Medicine in the 4th quarter worth about $5,479,000. Barclays PLC grew its holdings in shares of Disc Medicine by 123.7% during the 3rd quarter. Barclays PLC now owns 40,145 shares of the company's stock worth $1,972,000 after purchasing an additional 22,202 shares in the last quarter. Raymond James Financial Inc. acquired a new position in Disc Medicine in the fourth quarter valued at about $5,579,000. KLP Kapitalforvaltning AS acquired a new stake in Disc Medicine during the fourth quarter worth about $235,000. Finally, Wells Fargo & Company MN lifted its holdings in shares of Disc Medicine by 60.2% during the 4th quarter. Wells Fargo & Company MN now owns 20,778 shares of the company's stock worth $1,317,000 after acquiring an additional 7,808 shares during the period. 83.70% of the stock is currently owned by institutional investors.

Disc Medicine Stock Performance

Shares of NASDAQ IRON traded down $0.67 during midday trading on Monday, reaching $47.37. The stock had a trading volume of 132,011 shares, compared to its average volume of 347,391. Disc Medicine, Inc. has a twelve month low of $30.82 and a twelve month high of $68.73. The company's 50 day moving average price is $45.75 and its 200 day moving average price is $54.64. The firm has a market cap of $1.64 billion, a price-to-earnings ratio of -11.90 and a beta of 0.77.

Disc Medicine (NASDAQ:IRON - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($1.02) earnings per share for the quarter, missing the consensus estimate of ($0.99) by ($0.03). Equities analysts forecast that Disc Medicine, Inc. will post -4.07 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. TD Cowen assumed coverage on Disc Medicine in a research note on Thursday, February 27th. They issued a "buy" rating on the stock. Cantor Fitzgerald raised their target price on shares of Disc Medicine from $99.00 to $132.00 and gave the company an "overweight" rating in a research report on Tuesday, March 18th. Scotiabank raised their price objective on Disc Medicine from $73.00 to $75.00 and gave the company a "sector outperform" rating in a report on Monday, March 3rd. Morgan Stanley reiterated an "overweight" rating and issued a $85.00 target price on shares of Disc Medicine in a research report on Friday, March 7th. Finally, BMO Capital Markets raised their price objective on shares of Disc Medicine from $112.00 to $120.00 and gave the company an "outperform" rating in a report on Monday, May 12th. Ten investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Disc Medicine currently has an average rating of "Buy" and a consensus target price of $98.80.

Insider Transactions at Disc Medicine

In other news, Director Mona Ashiya sold 202,146 shares of the business's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $54.29, for a total transaction of $10,974,506.34. Following the completion of the sale, the director now owns 208,742 shares in the company, valued at $11,332,603.18. The trade was a 49.20% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider William Jacob Savage sold 2,100 shares of the stock in a transaction on Friday, May 2nd. The stock was sold at an average price of $50.17, for a total value of $105,357.00. Following the completion of the transaction, the insider now owns 66,398 shares in the company, valued at approximately $3,331,187.66. This represents a 3.07% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 349,510 shares of company stock valued at $18,936,535 in the last quarter. 4.24% of the stock is currently owned by company insiders.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.